Thus our results suggest that targeting of FOLRα alone by farletuzumab may not be sufficient to downregulate MDM2 function in gastric cancer and that the therapeutic efficacy of farletuzumab, even in combination with chemotherapy, may be limited. This evidence concerns the gene MDM2 and gastric cancer.